Vanessa Tyrrell

Vanessa Tyrrell

Auto-generated profile, based on publicly available information

Vanessa Tyrrell

Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LLLoretta Lau
Loretta Lau
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
CMChelsea Mayoh
Chelsea Mayoh
MWMarie Wong
Marie Wong
PBPaulette Barahona
Paulette Barahona
DZDavid Ziegler
David Ziegler
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here we report consecutive data from 384 patients with high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial. A total of 256 (67%) patients received PGT recommendations and 110 (29%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings (26% versus 5.2%; P = 0.003). PGT based on tier 1 evidence, PGT targeting fusions or commenced before disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers. ClinicalTrials.gov registration: NCT03336931

31 July 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
CMChelsea Mayoh
Chelsea Mayoh
JMJie Mao
Jie Mao
JXJinhan Xie
Jinhan Xie
GTGabor Tax
Gabor Tax
SCShu-Oi Chow
Shu-Oi Chow
EDEmmy Dolman
Emmy Dolman
For one-third of patients with pediatric cancer enrolled in precision medicine programs, molecular profiling does not result in a therapeutic recommendation. To identify potential strategies for treating these high-risk pediatric patients, we performed in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. Tumor cell expansion did not influence drug responses, and 82% of the screens on expanded tumor cells were completed while the patients were still under clinical care. High-throughput drug screening (HTS) confirmed known associations between activating genomic alterations in NTRK, BRAF, and ALK and responses to matching targeted drugs. The in vitro results were further validated in patient-derived xenograft models in vivo and were consistent with clinical responses in treated patients. In addition, effective combinations could be predicted by correlating sensitivity profiles between drugs. Furthermore, molecular integration with HTS identified biomarkers of sensitivity to WEE1 and MEK inhibition. Incorporating HTS into precision medicine programs is a powerful tool to accelerate the improved identification of effective biomarker-driven therapeutic strategies for treating high-risk pediatric cancers. Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.

19 September 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CWClaire E Wakefield
Claire E Wakefield
KHKate Hetherington
Kate Hetherington
EREden Grace Robertson
Eden Grace Robertson
MDMark W. Donoghoe
Mark W. Donoghoe
Jacqueline HunterJacqueline Hunter
Jacqueline Hunter
DZDavid Ziegler
David Ziegler
Background: Paediatric precision oncology aims to match therapeutic agents to driver gene targets. We investigated whether parents and patients regret participation in precision medicine trials, particularly when their hopes are unfulfilled.Methods: Parents and adolescent patients completed questionnaires at trial enrolment (T0) and after receiving results (T1). Parents opted-in to an interview at T1. Bereaved parents completed a questionnaire 6-months post-bereavement (T1B). We analysed quantitative data with R and qualitative data thematically with NVivo, before integrating all data for interpretation.Results: 182 parents and 23 patients completed T0; 108/182 parents and 8/23 patients completed T1; 27/98 bereaved parents completed T1B; and 45/108 parents were interviewed. At enrolment, participants held concurrent hopes that precision medicine would benefit future children and their child. Participants expressed concern regarding wait-times for receipt of results. Most participants found the trial beneficial and not burdensome, including bereaved parents. Participants reported high trial satisfaction (median scores: parents: 93/100; patients: 80/100). Participants expressed few regrets (parent median scores: parents: 10/100; bereaved parents: 15/100; patient regret: 2/8 expressed minimal regret).Conclusions: Even when trial outcomes did not match their hopes, parents and patients rarely regretted participating in a childhood cancer precision medicine trial. These data are critical for integrating participants’ views into future precision medicine delivery.

5 October 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
COChristopher E. L. Owens
Christopher E. L. Owens
OTOwen Tan
Owen Tan
JKJoice Kuroiwa-Trzmielina
Joice Kuroiwa-Trzmielina
RSRupendra N. Shrestha
Rupendra N. Shrestha
TOTracey O’bRien
Tracey O’bRien
DSDeborah J. Schofield
Deborah J. Schofield
Embedding precision medicine in paediatric oncology shows promise to have a positive impact on how children with cancer will be treated in the future. While there are a number of studies of precision medicine in childhood cancer, there is limited evidence available on the cost of implementing the related testing. This is the first Australian study that systematically measures the cost of using precision medicine in the care of high-risk childhood cancers, through the Zero Childhood Cancer Precision Medicine Programme. In 2021 Australian dollars, the estimated costs inclusive of genomic and preclinical testing were: (A) $12,743 per patient for access; (B) $14,262 per identification of molecular cause; and (C) $21,769 per MTB recommendation. The information gained supports the understanding of the cost of reporting clinically significant outcomes relevant to the biology of the tumour, diagnosis, prognosis and potentially improving clinical management for a child.

13 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
NFNoemi A. Fuentes-Bolanos
Noemi A. Fuentes-Bolanos
ECEliza K. Courtney
Eliza K. Courtney
CMChelsea Mayoh
Chelsea Mayoh
MWMeera Warby
Meera Warby
LLLoretta Lau
Loretta Lau
DZDavid Ziegler
David Ziegler
Purpose: The role of germline predisposition in pediatric cancer is increasingly recognized. However, the optimal approach to identifying cancer predisposing germline pathogenic variants (GPV) in children, and even the prevalence of GPVs among children with cancer, remain unclear. We examined GPV prevalence and diagnostic yield of different test approaches within a national pediatric precision oncology program. Experimental Design: We performed prospective rapid-turnaround whole-genome and -transcriptome profiling of 496 consecutively recruited children with poor-prognosis cancer to identify genetic variants linked to cancer risk. Results: Integration of tumor and germline molecular profiling identified GPVs in 15.5% of patients, an incremental GPV yield of 7.9% above that detected by standard care. Although the cancer type was outside the recognized phenotypic spectrum for 43.7% of reported GPVs, 63.2% of these were clinically actionable. Integrated germline-tumor analysis increased the GPV detection rate by 8.5%, informed germline interpretation in 14.3% of patients with GPVs, and provided biological insight into tumor etiology, together highlighting the value of integrated analyses. Cascade testing in first-degree relatives confirmed that the GPV was de novo in 21% of tested families. Within inherited GPVs (73.9%), 47.8% had direct implications for risk management recommendations in the relevant parent. Conclusions: Our findings establish the clinical benefit and feasibility of integrated tumor–germline whole-genome screening to detect GPVs in children with poor-prognosis cancers and their first-degree relatives.

17 February 2025 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
KBKristine Barlow-Stewart
Kristine Barlow-Stewart
ECEliza Courtney
Eliza Courtney
MCMark Cowley
Mark Cowley
CECamron Ebzery
Camron Ebzery
NBNoemi Fuentes Bolanos
Noemi Fuentes Bolanos
CJCarolyn Johnston
Carolyn Johnston
In pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child’s raw data and/or biospecimen. To satisfy such requests, the ZERO Childhood Cancer Program required a guidance document. Literature review led to Version(V)1; Delphi consultation with 21/54 invited experts (V2–4) and parent consultations (V5–6). A final V7 was approved for implementation: Policy (purpose; background; ethical considerations), Process (nine steps), and consent form. Issues addressed included: child’s best interests, clinical utility, non-maleficence, reciprocity between researchers and participants/parents; responsibility to genetic relatives; acknowledging potential value of subsequent analysis/interpretation but no obligation on treating clinicians to act on therapeutic recommendations arising; practical barriers to return; and supporting parental empowerment by facilitating meeting with a study genetic counselor, separate from their treating clinician, if preferred, to manage their request. This guide may be a model for other research groups and inform ethical guidelines.